Early clopidogrel use in non-ST elevation acute coronary syndrome and subsequent coronary artery bypass grafting

Area of Science:

• Cardiology
• Pharmacology
• Clinical Medicine

Background:

• Clopidogrel is recommended for non-ST elevation acute coronary syndromes (NSTE-ACS) to reduce major adverse cardiac events.
• Current guidelines recommend early clopidogrel use in NSTE-ACS patients.
• Concerns about perioperative bleeding during coronary artery bypass grafting (CABG) limit clopidogrel's uptake.

Purpose of the Study:

• To evaluate the safety and efficacy of early clopidogrel use in NSTE-ACS patients, particularly concerning subsequent CABG.
• To address the discrepancy between guideline recommendations and actual clopidogrel usage in NSTE-ACS.

Main Methods:

• Review of existing studies and data on clopidogrel use in NSTE-ACS patients.
• Analysis of perioperative bleeding risks associated with clopidogrel and CABG.
• Assessment of ischemic event rates in NSTE-ACS patients receiving clopidogrel versus those not.

Main Results:

• Clopidogrel use is linked to decreased major adverse cardiac events in NSTE-ACS.
• Increased bleeding risk with clopidogrel is primarily observed when administered within 5 days of CABG.
• Holding clopidogrel for 5 days before CABG is safe and does not increase ischemic events.
• Early clopidogrel use in NSTE-ACS patients referred for CABG reduces ischemic events compared to no clopidogrel.

Conclusions:

• Early clopidogrel administration is beneficial for NSTE-ACS patients, even those potentially undergoing CABG.
• A 5-day pre-CABG holding period for clopidogrel is safe and effective in managing bleeding risks.
• Guidelines should support early clopidogrel use in NSTE-ACS, challenging the practice of withholding it pending CABG decisions.